ClinicalTrials.gg
CompletedNCT06344104BaxAsiaUpdated Apr 21, 2026

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

A Phase 3 interventional study of Baxdrostat and Placebo in Uncontrolled Hypertension and Resistant Hypertension, sponsored by AstraZeneca. Completed at 93 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.

Enrollment
4th of 18
326 · median 197
Started
2024
with 3 others
Phase 3
6 of 18
2 open now
Registered
15th of 18
by date
Lead sponsor
16 of 18
AstraZeneca

Among the 18 studies testing baxdrostat in Hypertension, this one is the 4th largest by enrollment, is one of 4 that started in 2024, is one of 6 in phase 3, and was the 15th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About baxdrostat

baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baxdrostat in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to measure the efficacy and safety of baxdrostat in participants with uHTN or rHTN. The main objective is to compare the difference in SBP change from baseline at Week 12 of treatment between participants receiving 2 mg baxdrostat or 1 mg baxdrostat tablets and participants receiving placebo tablets.

Read the detailed description

This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered QD orally, on the reduction of SBP in approximately 300 participants aged ≥ 18 years with HTN (≥ 140 mmHg at Screening; ≥ 135 mmHg at randomisation) despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uHTN); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (rHTN).

03

Conditions studied

  • Uncontrolled Hypertension
  • Resistant Hypertension

Browse trials for

Keywords

  • Hypertension
  • Uncontrolled hypertension
  • Resistant hypertension
  • Blood pressure
  • Baxdrostat
  • CIN-107
  • Aldosterone
  • Aldosterone synthase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants must be ≥ 18 years old.
  • Mean seated SBP on automated office blood pressure measurement (AOBPM) ≥ 140 mmHg at Screening.
  • Fulfil at least 1 of the following 2 criteria:

    1. uHTN subpopulation: have a stable regimen (≥ 4 weeks) of 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator.
    2. rHTN subpopulation: have a stable regimen (≥ 4 weeks) of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator.
  • Estimated ≥ 45 mL/min/1.73m2 at Screening.
  • Serum potassium (K+) level ≥ 3.5 and \< 5.0 mmol/L at Screening.• Mean seated SBP on AOBPM ≥ 135 mmHg at Baseline.

Exclusion criteria

Exclusion Criteria:

  • Mean seated SBP on AOBPM ≥ 170 mmHg.
  • Mean seated DBP on AOBPM ≥ 105 mmHg.
  • Serum sodium level (Na+) \< 135 mmol/L at Screening.
  • Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation.
  • functional heart failure class IV at Screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
326 participants (actual)

Study arms

  • Experimental
    2 mg baxdrostat

    2 mg baxdrostat administered orally, once daily (QD)

    Drug: Baxdrostat

  • Experimental
    1 mg baxdrostat

    1 mg baxdrostat administered orally, once daily (QD).

    Drug: Baxdrostat

  • Placebo comparator
    placebo

    Placebo administered orally, once daily (QD)

    Drug: Placebo

Interventions

  • Baxdrostat tablet administered orally, once daily (QD). Unit dose strength: * 1 mg per tablet for 1mg baxdrostat Arm * 2 mg per tablet for 2mg baxdrostat Arm

    Also known as: CIN-107

  • DrugPlacebo

    Placebo tablet administered orally, once daily (QD).

06

What researchers measure

Primary outcomes

  1. Change from baseline in seated SBP at Week 12

    To assess the effect of 2 mg baxdrostat versus placebo on seated SBP at Week 12

    Time frame: At Week 12

Secondary outcomes

  1. Change from baseline in seated SBP at Week 12

    To assess the effect of 1 mg baxdrostat versus placebo on seated SBP at Week 12

    Time frame: At Week 12

  2. Change from RWD baseline (Week 24) in seated SBP at Week 32

    To assess the effect of 2 mg baxdrostat versus placebo on seated SBP at 8 weeks after randomised withdrawal

    Time frame: At Week 32

  3. Change from baseline in the mean ambulatory 24-hour SBP at Week 12 as measured by ABPM

    To assess the effect of treatment with baxdrostat 2 mg vs placebo on ambulatory 24-hour average SBP at Week 12

    Time frame: At Week 12

  4. Change from baseline in the mean ambulatory 24-hour SBP at Week 12 as measured by ABPM

    To assess the effect of treatment with baxdrostat 1 mg vs placebo on ambulatory 24-hour average SBP at Week 12

    Time frame: At Week 12

  5. Change from baseline in seated DBP at Week 12

    To assess the effect of 2 mg baxdrostat versus placebo on seated DBP at Week 12

    Time frame: At Week 12

  6. Achieving seated SBP < 140 mmHg at Week 12

    To assess the effect of 2 mg baxdrostat versus placebo on achieving seated SBP \< 140 mmHg at Week 12

    Time frame: At Week 12

  7. Change from baseline in seated DBP at Week 12

    To assess the effect of 1 mg baxdrostat versus placebo on seated DBP at Week 12

    Time frame: At Week 12

  8. Achieving seated SBP < 140 mmHg at Week 12

    To assess the effect of 1 mg baxdrostat versus placebo on achieving seated SBP \< 140 mmHg at Week 12

    Time frame: At Week 12

  9. Change from baseline in seated SBP at Week 12

    To assess the effect of 2 mg baxdrostat versus placebo on seated SBP at Week 12 in the rHTN subgroup

    Time frame: At Week 12

  10. Change from baseline in seated SBP at Week 12

    To assess the effect of 1 mg baxdrostat versus placebo on seated SBP at Week 12 in the rHTN subgroup

    Time frame: At Week 12

Other outcomes

  1. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of baxdrostat versus placebo. Occurrence of adverse events (AE), including serious adverse events (SAEs), adverse events leading to treatment discontinuation (DAE) and adverse events of special interest (AESI)

    Time frame: Up to week 54

07

Study locations

93 sites
  • Research Site
    Bahía Blanca, 8000, Argentina
  • Research Site
    CABA, C1426, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1419AHL, Argentina
  • Research Site
    San Miguel de Tucumán, T4000ICL, Argentina
  • Research Site
    San Nicolás de los Arroyos, B2900DPA, Argentina
  • Research Site
    Coffs Harbour, 02450, Australia
  • Research Site
    Gosford, 2250, Australia
  • Research Site
    Hoppers Crossing, 3029, Australia
  • Research Site
    Ipswich, 4305, Australia
  • Research Site
    Baotou, 014010, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changde, 415000, China
  • Research Site
    Changsha, 410015, China
  • Research Site
    Changsha, 430033, China
  • Research Site
    Changzhou, 272100, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400010, China
  • Research Site
    Chongqing, 400014, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Deyang, 618000, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Hangzhou, 310014, China
  • Research Site
    Ha’erbin, 150001, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Heze, 274099, China
  • Research Site
    Jiujiang, 332000, China
  • Research Site
    Luoyang, 471000, China
  • Research Site
    Meihekou, 135022, China
  • Research Site
    Nanchang, 330009, China
  • Research Site
    Nanchong, 637900, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Panjin, 124009, China
  • Research Site
    Sanya, 572000, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Shenyang, 110004, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Taiyuan, 030024, China
  • Research Site
    Tianjin, 300457, China
  • Research Site
    Tianjin, China
  • Research Site
    Wuhan, 430010, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430060, China
  • Research Site
    Xianyang, 712000, China
  • Research Site
    Xianyang, 750004, China
  • Research Site
    Xuzhou, 221000, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Yinchuan, 750001, China
  • Research Site
    Zigong, 643021, China
  • Research Site
    Hong Kong, 00000, Hong Kong
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Bangalore, 560 092, India
  • Research Site
    Belagavi, 590016, India
  • Research Site
    Chūōku, 103-0027, Japan
  • Research Site
    Chūōku, 260-0804, Japan
  • Research Site
    Hamamatsu, 430-0929, Japan
  • Research Site
    Kagoshima, 890-8520, Japan
  • Research Site
    Koga-shi, 306-0232, Japan
  • Research Site
    Meguro-ku, 153-0051, Japan
  • Research Site
    Minatoku, 108-0073, Japan
  • Research Site
    Minokamo Shi, 505-8510, Japan
  • Research Site
    Osaka, 530-8480, Japan
  • Research Site
    Toshima-ku, 171-0014, Japan
  • Research Site
    Tsukuba, 305-0861, Japan
  • Research Site
    Yokohama, 236-0004, Japan
  • Research Site
    Iloilo City, 5000, Philippines
  • Research Site
    Quezon City, 1112, Philippines
  • Research Site
    Ivanovo, 153012, Russia
  • Research Site
    Moscow, 111539, Russia
  • Research Site
    Moscow, 119991, Russia
  • Research Site
    Moscow, 121552, Russia
  • Research Site
    Moscow, 129327, Russia
  • Research Site
    Saint Petersburg, 195067, Russia
  • Research Site
    Saint Petersburg, 197341, Russia
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 04763, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Ankara, 06800, Turkey (Türkiye)
  • Research Site
    Ankara, 5000, Turkey (Türkiye)
  • Research Site
    Cordaleo, 35575, Turkey (Türkiye)
  • Research Site
    Edirne, 22030, Turkey (Türkiye)
  • Research Site
    Kahramanmaraş, 46100, Turkey (Türkiye)
  • Research Site
    Kayseri, 38039, Turkey (Türkiye)
  • Research Site
    Kocaeli, 41380, Turkey (Türkiye)
  • Research Site
    Mersin, 33343, Turkey (Türkiye)
  • Research Site
    Can Tho, 900000, Vietnam
  • Research Site
    Hanoi, 100000, Vietnam
  • Research Site
    Ho Chi Minh City, 700000, Vietnam
  • Research Site
    Hochiminh City, 700000, Vietnam
  • Research Site
    Hochiminh, 70000, Vietnam
08

References and documents

Publications

  • Flack JM, Azizi M, Brown JM, Dwyer JP, Jones ESW, Lihn AS, Liu L, Olsson DS, Perl S, Shibata H, Wang JG, Wilderang U, Wittes JT, Williams B. Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertens Res. 2025 Nov;48(11):2911-2923. doi: 10.1038/s41440-025-02297-7. Epub 2025 Aug 25. PubMed 40850955 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Nov 2025, 19 months.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 19 months is close to that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2024
First posted
Apr 3, 2024
StartActual
Apr 8, 2024
Primary completionActual
Nov 24, 2025
CompletionActual
Apr 3, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06344104
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
Apr 8, 2024
Primary completion
Nov 24, 2025
Completion
Apr 3, 2026
Last update
Apr 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion